These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 17602702)

  • 1. Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.
    Zhou Y; Drummond DC; Zou H; Hayes ME; Adams GP; Kirpotin DB; Marks JD
    J Mol Biol; 2007 Aug; 371(4):934-47. PubMed ID: 17602702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Construction and screening of phage antibody libraries against epidermal growth factor receptor and soluble expression of single chain Fv].
    Sheng WJ; Miao QF; Zhen YS
    Yao Xue Xue Bao; 2009 Jun; 44(6):597-602. PubMed ID: 19806889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach.
    Lehmann A; Wixted JH; Shapovalov MV; Roder H; Dunbrack RL; Robinson MK
    MAbs; 2015; 7(6):1058-71. PubMed ID: 26337947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule.
    Friedman M; Orlova A; Johansson E; Eriksson TL; Höidén-Guthenberg I; Tolmachev V; Nilsson FY; Ståhl S
    J Mol Biol; 2008 Mar; 376(5):1388-402. PubMed ID: 18207161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
    Nielsen UB; Adams GP; Weiner LM; Marks JD
    Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radionuclide therapy using ¹³¹I-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression.
    Li W; Liu Z; Li C; Li N; Fang L; Chang J; Tan J
    J Cancer Res Clin Oncol; 2016 Mar; 142(3):619-32. PubMed ID: 26573511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A collagen-binding EGFR single-chain Fv antibody fragment for the targeted cancer therapy.
    Liang H; Li X; Chen B; Wang B; Zhao Y; Zhuang Y; Shen H; Zhang Z; Dai J
    J Control Release; 2015 Jul; 209():101-9. PubMed ID: 25916496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
    Kuan CT; Reist CJ; Foulon CF; Lorimer IA; Archer G; Pegram CN; Pastan I; Zalutsky MR; Bigner DD
    Clin Cancer Res; 1999 Jun; 5(6):1539-49. PubMed ID: 10389943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site.
    Schier R; McCall A; Adams GP; Marshall KW; Merritt H; Yim M; Crawford RS; Weiner LM; Marks C; Marks JD
    J Mol Biol; 1996 Nov; 263(4):551-67. PubMed ID: 8918938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells.
    Jannot CB; Beerli RR; Mason S; Gullick WJ; Hynes NE
    Oncogene; 1996 Jul; 13(2):275-82. PubMed ID: 8710366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel multivalent (99m)Tc-labeled EG2-C4bpα antibody for targeting the epidermal growth factor receptor in tumor xenografts.
    Li C; Zhang Y; Wang L; Feng H; Xia X; Ma J; Yuan H; Gao B; Lan X
    Nucl Med Biol; 2015 Jun; 42(6):547-54. PubMed ID: 25779037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
    Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
    Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
    Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
    Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection.
    Schier R; Bye J; Apell G; McCall A; Adams GP; Malmqvist M; Weiner LM; Marks JD
    J Mol Biol; 1996 Jan; 255(1):28-43. PubMed ID: 8568873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Directed evolution, phage display and combination of evolved mutants: a strategy to recover the neutralization properties of the scFv version of BCF2 a neutralizing monoclonal antibody specific to scorpion toxin Cn2.
    Juárez-González VR; Riaño-Umbarila L; Quintero-Hernández V; Olamendi-Portugal T; Ortiz-León M; Ortíz E; Possani LD; Becerril B
    J Mol Biol; 2005 Mar; 346(5):1287-97. PubMed ID: 15713481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
    Sheng W; Shang Y; Li L; Zhen Y
    Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth.
    Müller N; Hartmann C; Genssler S; Koch J; Kinner A; Grez M; Wels WS
    Int J Cancer; 2014 Jun; 134(11):2547-59. PubMed ID: 24243620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging.
    Orcutt KD; Slusarczyk AL; Cieslewicz M; Ruiz-Yi B; Bhushan KR; Frangioni JV; Wittrup KD
    Nucl Med Biol; 2011 Feb; 38(2):223-33. PubMed ID: 21315278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.